Kairos Pharma Quote - KAPA

Rendering Error

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.923

Bid

Ask

Volume

316,944

0.92 Day's Range 1.03

0.8506 52 Week Range 4.00

Market Cap

11.858M

Previous Close

0.9074

Open

0.94

Last Trade

272

0.96

Last Trade Time

Financial Volume

US$ 304,279

VWAP

0.960042

Average Volume (3m)

397,148

Shares Outstanding

12,846,785

Dividend Yield

PE Ratio

-6.74

Earnings Per Share (EPS)

-0.14

Revenue

Net Profit

-1.81M

Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, bre... Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. In June 2021, Kairos acquired Enviro Therapeutics through a share exchange. The acquisition allowed us to incorporate into our company Enviros advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

kairospharma.com

Headquarters

Wilmington, Delaware, USA

Founded

Kairos Pharma Ltd is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker KAPA. The last closing price for Kairos Pharma was US$0.91. Over the last year, Kairos Pharma shares have traded in a share price range of US$ 0.8506 to US$ 4.00.

Kairos Pharma currently has 12,846,785 shares outstanding. The market capitalization of Kairos Pharma is US$11.66 million. Kairos Pharma has a price to earnings ratio (PE ratio) of -6.74.

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Company expects safety data readout in 2025 as Randomized Arm continues enrollment at key medical centers Kairos Pharma, Ltd. (NYSE American:...

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and...

Form 8-K - Current report

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a peer-reviewed publication highlighting a...

Form 8-K - Current report

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that the company presented preclinical data on...

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.047	-4.84536082474	0.97	1.05	0.8844	75614	0.96275693	CS
4	0.0012	0.130180082447	0.9218	1.25	0.88	137399	1.01055418	CS
12	-0.657	-41.582278481	1.58	1.92	0.8506	397148	1.52846382	CS
26	-0.567	-38.0536912752	1.49	3.25	0.8506	1309592	2.00489983	CS
52	-3.077	-76.925	4	4	0.8506	1137334	2.00307344	CS
156	-3.077	-76.925	4	4	0.8506	1137334	2.00307344	CS
260	-3.077	-76.925	4	4	0.8506	1137334	2.00307344	CS

KAPA - Frequently Asked Questions (FAQ)

What is the current Kairos Pharma share price?

The current share price of Kairos Pharma is US$ 0.923

How many Kairos Pharma shares are in issue?

Kairos Pharma has 12,846,785 shares in issue

What is the market cap of Kairos Pharma?

The market capitalisation of Kairos Pharma is USD 11.66M

What is the 1 year trading range for Kairos Pharma share price?

Kairos Pharma has traded in the range of US$ 0.8506 to US$ 4.00 during the past year

What is the PE ratio of Kairos Pharma?

The price to earnings ratio of Kairos Pharma is -6.74

What is the reporting currency for Kairos Pharma?

Kairos Pharma reports financial results in USD

What is the latest annual profit for Kairos Pharma?

The latest annual profit of Kairos Pharma is USD -1.81M

What is the registered address of Kairos Pharma?

The registered address for Kairos Pharma is 108 W. 13TH STREET SUITE 100, WILMINGTON, DELAWARE, 19801

What is the Kairos Pharma website address?

The website address for Kairos Pharma is kairospharma.com

Which industry sector does Kairos Pharma operate in?

Kairos Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
FLAGGlobal X S&P 500 US Market Leaders Top 50 ETF	US$ 24.69 (208.63%)	1.46k
BTTRBetter Choice Company Inc	US$ 2.025 (46.20%)	315.77k
CHROChannel Therapeutics Corporation	US$ 1.76 (40.24%)	39.58M
LLYXDefiance Daily Target 2X Long LLY ETF	US$ 19.57 (28.50%)	881.26k
DJTUT REX 2X Long DJT Daily Target ETF	US$ 19.17 (24.36%)	85.52k
FOXOFOXO Technologies Inc	US$ 0.0841 (-22.84%)	1.65M
NVOXDefiance Daily Target 2x Long Nvo ETF	US$ 4.82 (-15.69%)	282.82k
AZTRAzitra Inc	US$ 0.28 (-11.95%)	381.57k
PTNPalatin Technologies Inc New	US$ 0.217001 (-11.79%)	13.13M
TOPPToppoint Holdings Inc	US$ 1.08 (-11.48%)	6.36k
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 9.20 (-1.50%)	233.66M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 7.7151 (-0.06%)	83.19M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 3.66 (0.14%)	78.84M
SPYSPDR S&P 500	US$ 526.41 (0.14%)	78.53M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF	US$ 3.57 (6.09%)	69.9M